← All companies
CORCEPT THERAPEUTICS INC
CORT - CIK 0001088856
Market cap$8.39 B
Rank#1039
SEC filings1,955
CORCEPT THERAPEUTICS INC trades as CORT and has a market capitalization of $8.39 B, making it the #1039 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $761.41M, up 12.8% from the prior year and net income of $99.65M. This page tracks CORCEPT THERAPEUTICS INC through 1,955 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$761.41MFY 2025
Net income (latest FY)$99.65MFY 2025
Operating cash flow (latest FY)$142.00MFY 2025
Total assets (latest FY)$836.65MFY 2025
Net margin13.1%latest FY
Financial performance
Over the last 9 fiscal years CORCEPT THERAPEUTICS INC's revenue grew from $81.32M to $761.41M, a compound annual growth rate of 28.2%. Net profit margin expanded from 10.0% to 13.1% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $8.39 B
- Share price (derived)market cap / shares outstanding
- $78.12
- P/E ratio (trailing FY)
- 84.2
- EPS (diluted)FY 2025
- $0.82
- Shares outstandingas of 2026-04-23
- 0.11B
- Total equityas of 2026-03-31
- $637.99M
- Return on equity
- 15.6%
- Cash & equivalentsas of 2026-03-31
- $108.74M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-20 |
Recent press releases
- Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure2026-05-29
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure – Corcept Therapeutics, Incorporated
- Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome2026-05-27
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome – Corcept Therapeutics, Incorporated
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update2026-04-30
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update – Corcept Therapeutics, Incorporated
- Corcept Phase 2 Study Dazucorilant Demonstrates Two Year Overall2026-04-30
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis – Corcept Therapeutics, Incorporated
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call2026-04-23
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
Similar companies
The largest companies sharing CORCEPT THERAPEUTICS INC's SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is CORCEPT THERAPEUTICS INC's market cap?
CORCEPT THERAPEUTICS INC (CORT) has a market capitalization of $8.39 B as of 2026-06-10, ranking #1039 among US-listed companies.
How much revenue does CORCEPT THERAPEUTICS INC make?
CORCEPT THERAPEUTICS INC reported revenue of $761.41M for fiscal year 2025, an increase of 12.8% year over year.
Is CORCEPT THERAPEUTICS INC profitable?
Yes. CORCEPT THERAPEUTICS INC reported net income of $99.65M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.